20.54
-4.42%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About DaShenLin Pharmaceutical Group Co
Its shares trade on Shanghai under the ticker 603233.SS. It has been listed since 31 July 2017. In the fiscal year to 31 December 2025, it reported revenue of CN¥27.50bn and net income of CN¥1.24bn. At that date it held total assets of CN¥26.49bn and shareholders' equity of CN¥7.37bn.
DaShenLin Pharmaceutical Group Co., Ltd. engages in the retail and wholesale of pharmaceutical products. The company is headquartered in Guangzhou, Guangdong. The company went IPO on 2017-07-31. The firm's primary business includes direct sales and retailing of Chinese and Western medicine, ginseng nourishing herbs and Chinese medicine pieces, health products, medical apparatus and instruments and other commodities. The firm mainly conducts its business within domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Consumer Staples
- Industry
- Consumer Staples Distribution & Retail
- Listed since
- 31 Jul 2017
- Employees
- 39,499
- Website
- dslyy.com ↗
Leadership
Pay as last reported
- Mr. Yunfeng KeChairman of the Board, since 2016CN¥2.5m
- Mr. Guangzhi PengChief Financial Officer, Secretary of the BoardCN¥889,100
- Mr. Guoqiang KeGeneral Manager, DirectorCN¥2.3m
- Ms. Qunfei TanDeputy General Manager, Director, since 2016CN¥2.0m
- Mr. Changcheng ChenDeputy General Manager, General Manager - CenterCN¥2.1m
- Mr. Hong ChenDeputy General ManagerCN¥1.5m
- Ms. Xin JiangDeputy General ManagerCN¥2.0m
- Mr. Tuoji KeDeputy General Manager, General Manager - Shenzhen Operations RegionCN¥1.8m
- Mr. Jie LiDirector
- Mr. Guochang LiuIndependent DirectorCN¥73,400
- Mr. Liping LuIndependent DirectorCN¥80,000
- Mr. Zuyao SuIndependent DirectorCN¥80,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 60
- Environment
- 49
- Social
- 75
- Governance
- 56
- Direct emissions (scope 1)
- 5,220.48 t
- Energy emissions (scope 2)
- 14,082.59 t
- Women in the workforce
- 86.27%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- DaShenLin Pharmaceutical Group employs 39,499 full-time employees in Guangzhou, China.
- The company focuses on retail and wholesale of pharmaceutical products including Chinese and Western medicine.
- DaShenLin operates primarily within the domestic Chinese market for its retail and wholesale business.
Weaknesses
- The company's business is limited to the domestic Chinese market with no international expansion mentioned.
- DaShenLin's primary business relies on direct sales and retailing without diversification into other sectors.
- The firm has no mention of international presence or global market strategies.
Opportunities
- The domestic Chinese market offers significant growth potential for pharmaceutical retail and wholesale businesses.
- Expanding into international markets could leverage DaShenLin's expertise in Chinese medicine products.
- Growing demand for health products and medical apparatus in China presents new opportunities.
Threats
- The domestic Chinese market faces intense competition from other pharmaceutical retailers.
- Regulatory changes in China's pharmaceutical industry could impact DaShenLin's operations.
- Economic downturns in China may reduce consumer spending on health products and medical apparatus.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.